^
    3ms
    Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy (clinicaltrials.gov)
    P1, N=13, Suspended, The Methodist Hospital Research Institute | Trial completion date: Dec 2025 --> Mar 2025 | Recruiting --> Suspended | Trial primary completion date: Dec 2024 --> Aug 2024
    Trial completion date • Trial suspension • Trial primary completion date • Gene therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • ADV/IL-12 gene therapy
    9ms
    Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy (clinicaltrials.gov)
    P1, N=16, Recruiting, The Methodist Hospital Research Institute | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Gene therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • ADV/IL-12 gene therapy
    over1year
    Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy (clinicaltrials.gov)
    P1, N=16, Recruiting, The Methodist Hospital Research Institute | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Dec 2023
    Trial completion date • Trial primary completion date • Gene therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • ADV/IL-12 gene therapy
    3years
    Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy (clinicaltrials.gov)
    P1, N=16, Recruiting, The Methodist Hospital Research Institute | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • ADV/IL-12 gene therapy
    3years
    Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, The Methodist Hospital Research Institute | Initiation date: Jun 2021 --> Sep 2021
    Clinical • Trial initiation date
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • ADV/IL-12 gene therapy
    over3years
    Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, Eric Bernicker, MD
    Clinical • New P1 trial
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • ADV/IL-12 gene therapy